Zydus gets USFDA nod for generic acne treatment drug
The drug firm has received final approval from the US Food and Drug Administration (USFDA) for Isotretinoin Capsules USP (10 mg, 20 mg 30 mg and 40 mg), it said in a statement.
Zydus Lifesciences on Thursday said it has received approval from the US health regulator to market a generic product to treat acne in the American market.
The drug firm has received final approval from the US Food and Drug Administration (USFDA) for Isotretinoin Capsules USP (10 mg, 20 mg 30 mg and 40 mg), it said in a statement.
Isotretinoin capsules are used to treat severe cystic acne that has not responded to other treatments.
The drug will be manufactured at Zydus' formulation manufacturing facility in Moraiya, Ahmedabad.
As per the IQVIA MAT data, Isotretinoin Capsules had annual sales of USD 165 million in the US.
Shares of Zydus Lifesciences were trading 0.13 per cent down at Rs 627.35 apiece on the BSE.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
SBI 444-day FD vs Union Bank of India 333-day FD: Know maturity amount on Rs 4 lakh and Rs 8 lakh investments for general and senior citizens
Power of Compounding: Salary Rs 25,000 per month; is it possible to create over Rs 2.60 crore corpus; understand it through calculations
New Year Pick by Anil Singhvi: This smallcap stock can offer up to 75% return in long term - Check targets
Power of Compounding: How many years it will take to reach Rs 2 crore corpus if your monthly SIP is Rs 3,000, Rs 4,000, or Rs 5,000
Retirement Calculator: 40 years of age, Rs 50,000 monthly expenses; what should be retirement corpus and monthly investment
03:49 PM IST